Screenshot_20260704_160320_Drive.jpg
Analyze lft
analyse_media
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
I now have enough information to provide a thorough analysis. Here is the complete LFT interpretation:
LFT Analysis - Mrs. Chanda Kalro, 67F (Dated: 03-07-2026)
Results at a Glance
| Parameter | Result | Reference | Status |
|---|---|---|---|
| Bilirubin - Total | 0.61 mg/dL | 0.1-1.0 | Normal |
| Bilirubin - Direct | 0.32 mg/dL | 0.0-0.4 | Normal |
| Bilirubin - Indirect | 0.29 mg/dL | <1.0 | Normal |
| SGOT (AST) | 15.70 U/L | 0.1-31 | Normal |
| SGPT (ALT) | 22.40 U/L | <34 | Normal |
| Alkaline Phosphatase (ALP) | 136.0 U/L | 35-105 | HIGH |
| GGT | 338.50 U/L | 10-54 | HIGH |
| Total Protein | 7.18 g/dL | 6.4-8.3 | Normal |
| Albumin | 4.41 g/dL | 3.2-4.6 | Normal |
| Globulin | 2.77 g/dL | 1.9-3.9 | Normal |
| A:G Ratio | 1.59 | 1.1-2.5 | Normal |
Key Findings
Two abnormal values stand out:
1. GGT: 338.50 U/L (reference 10-54) - elevated ~6.3x the upper limit
This is the most striking abnormality. GGT is a highly sensitive marker for hepatobiliary disease and is found in the liver, biliary epithelium, kidneys, and pancreas. An elevation this significant points strongly to either:
- Biliary obstruction (intra- or extrahepatic cholestasis)
- Alcohol-related liver disease (GGT is classically the most sensitive enzyme for alcohol-induced liver injury)
- Non-alcoholic fatty liver disease (NAFLD/NASH) - common in older women
- Medications (anticonvulsants, statins, antibiotics)
- Primary biliary cholangitis (PBC) - relevant in a 67-year-old woman
2. ALP: 136.0 U/L (reference 35-105) - elevated ~1.3x the upper limit (modest elevation)
The concurrent elevation of both ALP and GGT is highly informative. Since GGT is also elevated, a hepatobiliary source for the ALP elevation is confirmed (Goldman-Cecil Medicine). Non-hepatic ALP elevation from bone, placenta, or intestine is effectively ruled out by the elevated GGT.
As per Goldman-Cecil Medicine (p. 1041-1043):
- Modest ALP increases (up to 3x ULN) occur in hepatitis and cirrhosis.
- Greater increases (3-10x ULN) usually indicate obstruction of bile flow.
- This patient's ALP is only ~1.3x ULN, but GGT is ~6.3x ULN - suggesting a predominantly GGT-driven cholestatic or toxic pattern.
Reassuring Features
- Bilirubin is normal - no jaundice/icterus at present
- SGOT and SGPT are normal - hepatocellular necrosis/inflammation is not the dominant process (no acute hepatitis picture)
- Albumin 4.41 g/dL - excellent synthetic function of the liver; no cirrhosis-related impairment
- A:G ratio 1.59 - normal, no evidence of chronic inflammatory state or cirrhosis
- AST/ALT ratio = 15.7/22.4 = 0.70 - this is <1, which argues against alcoholic liver disease (where the ratio is typically ≥2)
Pattern Interpretation
This LFT shows a cholestatic pattern (disproportionate ALP + GGT elevation with normal bilirubin and normal transaminases), not a hepatocellular pattern. The markedly elevated GGT with only modestly elevated ALP and entirely normal bilirubin/transaminases is commonly seen in:
- Biliary tract disease - gallstones, common bile duct stone, biliary stricture (most common in a 67F)
- Non-alcoholic fatty liver disease (NAFLD) - very prevalent at this age
- Drug/medication-induced - several common medications (statins, NSAIDs, antiepileptics, antibiotics) elevate GGT
- Primary biliary cholangitis (PBC) - autoimmune, classically affects middle-aged to older women
- Infiltrative liver disease - granulomas, amyloidosis, early malignancy
The normal AST/ALT ratio (<1) makes alcohol-related disease less likely despite the high GGT.
Recommended Next Steps
The treating physician should consider:
- Ultrasound of the abdomen - to evaluate for biliary dilatation, gallstones, fatty infiltration, or space-occupying lesions
- MRCP if ultrasound suggests biliary pathology
- Medication review - identify any hepatotoxic drugs
- Anti-mitochondrial antibody (AMA) - to screen for primary biliary cholangitis
- Fasting lipid profile and HbA1c - to assess for metabolic syndrome/NAFLD workup
- Repeat LFTs in 4-8 weeks if no obvious cause found
Note: This is a report analysis for informational purposes. The patient should consult her treating physician for clinical correlation and further management. - Goldman-Cecil Medicine (Alkaline Phosphatase section, pp. 1038-1044)
This is a shared conversation. Sign in to Orris to start your own chat.